EUCTR2006-000907-41-HU进行中（未招募）不适用
A single dose, randomised, double blind, double dummy, placebo-controlled, three-period crossover clinical study, comparing the efficacy, safety and tolerability of Formoterol-HFA pMDI 12 microgram per actuation administered by means of a spacer device (AeroChamber Plus) with that of Formoterol-HFA pMDI 12 microgram per actuation in 5- to 12-year-old children with persistent moderate to severe asthma
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 42
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Written informed consent obtained by parent/legal guardian.
- •- Boys and girls aged 5 to 12 years inclusive.
- •- Clinical diagnosis of persistent moderate to severe asthma stable for at least 2 months, according to the Classification of Asthma Severity of the Global Initiative for Asthma, Updated 2005.
- •- Patient on a stable dose, same formulation, of an inhaled corticosteroid (ICS) for at least 2 months before the screening visit. The daily taken dose, and also the formulation, of this inhaled corticosteroid need to remain constant throughout the
- •- Patient free of an inhaled long-acting beta2-agonist (LABA) for at least 2 months before the screening visit.
- •- Patient free of an inhaled fixed combination” long-acting beta2-agonist plus corticosteroid pMDI or DPI for at least 2 months before the screening visit.
- •- FEV1 greater or equal to 60% and < 80% of the predicted normal value.
- •- If the patient has not respected the conventional wash-out of 8 hours for short-acting beta2-agonists at the Visit 1 and:
- •if the FEV1 measurement is greater or equal to 80%, there is the possibility to take into account a previous FEV1 measurement for his enrolment in the run-in period.
- •This one has to be greater than or equal to 60% and < 80% performed during the last month. In such a case, FEV1 will be retested at Visit 2 after a conventional short-acting beta2-agonist treatment wash-out. If the FEV1 is still again greater or equal to 80% of the predicted normal value the patient will not be randomised to treatments; in such a case only, if the change in FEV1 is less than 12% at Visit 1, this criterion will need to be met before Visit 2, after a conventional 8-hour wash-out.
- •- A change in FEV1 from (pre-salbutamol) baseline value greater than or equal to 12%, 30 minutes following inhalation of 200 µg of salbutamol pMDI.
- •- A cooperative attitude and ability to be trained in the proper use of a pMDI and spacer (AeroChamber Plus).
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •- Intake of an investigational drug within 2 months prior to screening visit.
- •- No or poor co-ordination of actuation and inhalation.
- •- Inability to perform spirometry.
- •- Unwilling, or potentially unreliable patients or patients with a history of non compliance to medical therapy.
- •- History of malignancy or treatment for malignancy within 5 years of the screening visit.
- •- Other significant concomitant medical condition, or paraclinical evaluation indicating a significant medical condition, which might compromise patient safety, compliance, and/or interfere with test treatments evaluation.
- •- Seasonal asthma or asthma occurring only during episodic exposure to an allergen.
- •- History of cystic fibrosis or bronchiectasis.
- •- Vaccination with live-attenuated virus within 2 months of the screening visit.
- •- Change in daily dose, dosing schedule, formulation of an inhaled corticosteroid in the previous 2 months, or during the run-in period.
- •- Use of an inhaled long-acting beta2-agonist in the previous 2 months, or during the run-in period.
- •- Use of an inhaled fixed combination” long-acting beta2-agonist plus corticosteroid pMDI or DPI in the previous 2 months, or during the run-in period.
- •- An acute asthma exacerbation in the previous 2 months, or during the run-in period.
- •- Respiratory tract infection in the previous 2 months or during the run-in period.
- •- Parenteral or oral corticosteroids in the previous 2 months or during the run-in period.
- •- Use of cromolyn sodium, nedocromil, leukotriene modifiers, ketotifen, theophylline (any formulation), inhaled anticholinergics, antibiotics for a lower respiratory tract
- •infection, oral or nebulized beta2-agonists, nebulized corticosteroids in the previous 2 months, or during the run-in period.
- •- Intolerance or past reaction to test treatments or excipients/propellant gases.
- •- Use of astemizole or terfenadine in the previous 2 months and use of any antihistamine during the run-in period.
研究者
相似试验
进行中（未招募）
1 期
A clinical trial to investigate the comparability of relief from methacholine-induced bronchoconstriction with CHF1535 100/6 µg NEXThaler® versus CHF1535 100/6 µg pMDI in asthmatic patients.MedDRA version: 19.1Level: PTClassification code 10003553Term: AsthmaSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersAsthmaEUCTR2016-003672-47-GBChiesi Farmaceutici S.p.A.60
进行中（未招募）
不适用
A single dose, randomized, double blind, double dummy, placebo controlled, three-period crossover clinical study, comparing the onset of relief from methacholine induced bronchoconstriction with fixed combination beclomethasone dipropionate 100 µg plus formoterol fumarate 6 µg/actuation pMDI with HFA-134a propellant (Foster) versus standard salbutamol pMDI 100 µg/actuation (Ventolin Evohaler) therapy in asthmatic patients. - MART 1 Maintenance And Reliever TherapyAshtmaMedDRA version: 9.1Level: LLTClassification code 10003553Term: AsthmaEUCTR2008-000905-12-ITCHIESI
进行中（未招募）
不适用
A single dose, randomized, double blind, double dummy, placebo controlled, three-period crossover clinical study, comparing the onset of relief from methacholine induced bronchoconstriction with fixed combination beclomethasone dipropionate 100 µg plus formoterol fumarate 6 µg/actuation pMDI with HFA-134a propellant (Foster®) versus standard salbutamol pMDI 100 µg/actuation (Ventolin® 100 µg) therapy in asthmatic patients - MART1AsthmaEUCTR2008-000905-12-GBCHIESI FARMACEUTICI S.p.A.54
招募中
Unknown
To evaluate the Pharmacodynamic Equivalence of the Test and Reference Metered Dose Inhalers Containing Albuterol Sulfate in Adult Patients with Stable Mild AsthmaCTRI/2024/03/064870Intech Biopharm Limited
已完成
不适用
To check the difference of two products that is product A (Xtenergy caffeine 60%, 200 mg caffeine/ Capsule) and product B (Natural caffeine extract 99%,200 mg caffeine/Capsule) in the healthy adult human beings.CTRI/2019/11/022135OmniActive Health Technologies Ltd26